Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report)’s share price traded up 66.8% on Friday . The company traded as high as $0.46 and last traded at $0.46. 3,358 shares were traded during mid-day trading, an increase of 281% from the average session volume of 882 shares. The stock had previously closed at $0.27.
Defence Therapeutics Stock Up 66.8 %
The firm’s 50-day simple moving average is $0.39 and its 200-day simple moving average is $0.49.
Defence Therapeutics Company Profile
Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.
Featured Stories
- Five stocks we like better than Defence Therapeutics
- What is the Shanghai Stock Exchange Composite Index?
- Power Up: Gaming Industry Expansion Fuels Stock Opportunities
- Investing in Travel Stocks Benefits
- These 3 Quirky ETFs May Be Strong Plays in 2025
- What is a SEC Filing?
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
